US stock futures flounder amid tech weakness, Fed caution
CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $53.34 million and currently trading at $1.90 per share, has announced a partial response in a patient with advanced non-small cell lung cancer (NSCLC) participating in its Phase 2 THIO-101 clinical trial. The trial evaluates the efficacy of ateganosine, sequenced with Regeneron’s immune checkpoint inhibitor cemiplimab, in patients resistant to immune therapy and chemotherapy.
The patient, treated for over 20 months, showed a decrease in tumor size of at least 30%, which is considered a partial response. "Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC," said Vlad Vitoc, M.D., Chairman and CEO of MAIA. The company confirmed the response with a second scan and expressed confidence in ateganosine as a potential therapeutic alternative for third-line NSCLC patients. According to InvestingPro, analysts have set price targets ranging from $10.27 to $14.00, suggesting significant upside potential if the treatment proves successful.
Data from the trial, with a cutoff date of May 15, 2025, revealed a median overall survival (OS) of 17.8 months among the 22 NSCLC patients who received at least one dose of ateganosine. This compares favorably to the standard-of-care chemotherapy treatments for NSCLC, which have shown an OS of 5 to 6 months in similar settings. While InvestingPro data shows the company maintains strong liquidity with a current ratio of 2.35, its overall financial health score remains weak as it continues to invest in research and development.
Ateganosine is a first-in-class investigational telomere-targeting agent, which induces selective cancer cell death and activates both innate and adaptive immune responses. The expansion of the THIO-101 pivotal Phase 2 trial will further assess the overall response rates in advanced NSCLC patients receiving third-line therapy.
MAIA is focused on developing targeted immunotherapies for cancer, with ateganosine as its lead program for patients with telomerase-positive cancer cells. The company maintains a strong balance sheet with more cash than debt, positioning it well for continued development efforts. The company cautions that statements regarding the future prospects of ateganosine are forward-looking and subject to risks and uncertainties.
This report is based on a press release statement and provides a factual overview of recent developments in MAIA Biotechnology’s clinical trial for ateganosine without any endorsement of claims.
In other recent news, MAIA Biotechnology has reported promising results from its THIO-101 Phase 2 clinical trial for ateganosine in combination with Regeneron’s cemiplimab, targeting advanced non-small cell lung cancer (NSCLC) patients. The trial data, released on May 15, 2025, highlighted a median overall survival of 17.8 months, significantly surpassing the typical 5 to 6 months observed with standard chemotherapy treatments. MAIA Biotechnology is optimistic about the potential for accelerated FDA approval of ateganosine, with a decision anticipated as early as next year. Additionally, the company has secured $669,500 and $1.08 million in separate private placements, which will support the continuation of their Phase II THIO-101 trial and general working capital. These financial maneuvers also included issuing warrants exercisable at future dates. Furthermore, MAIA Biotechnology has doubled its authorized common stock from 70 million to 150 million shares, a strategic move to enhance flexibility for future corporate activities. The company continues to be an emerging growth entity, focusing on innovative cancer treatments. Investors and analysts are closely monitoring these developments, which could significantly impact MAIA’s market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.